Circulating cell-free DNA in breast cancer: searching for hidden information towards precision medicine

Data de publicació

2022-04-01T17:46:20Z

2022-04-01T17:46:20Z

2021-02-10

2022-04-01T17:46:21Z

Resum

Breast cancer (BC) is a leading cause of death between women. Mortality is significantly raised due to drug resistance and metastasis, while personalized treatment options are obstructed by the limitations of conventional biopsy follow-up. Lately, research is focusing on circulating biomarkers as minimally invasive choices for diagnosis, prognosis and treatment monitoring. Circulating cell-free DNA (ccfDNA) is a promising liquid biopsy biomaterial of great potential as it is thought to mirror the tumor's lifespan; however, its clinical exploitation is burdened mainly by gaps in knowledge of its biology and specific characteristics. The current review aims to gather latest findings about the nature of ccfDNA and its multiple molecular and biological characteristics in breast cancer, covering basic and translational research and giving insights about its validity in a clinical setting.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

MDPI

Documents relacionats

Reproducció del document publicat a: https://doi.org/10.3390/cancers13040728

Cancers, 2021, vol. 13, num. 4, p. 728

https://doi.org/10.3390/cancers13040728

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

cc-by (c) Panagopoulou, Maria et al., 2021

https://creativecommons.org/licenses/by/4.0/

Aquest element apareix en la col·lecció o col·leccions següent(s)